SCHEMBL3083680

SCHEMBL3083680

Nc1ccc(S(=O)(=O)N2CCOCC2)cc1C1=CCCCC1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.52
KDM4E B2RXH2 1/20 0.52
POLB P06746 1/20 0.49
GAA P10253 3/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 2/20 0.47
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 6/20 0.46
HTR2C P28335 1/20 0.45
MAPK1 P28482 1/20 0.45
TSHR P16473 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093846 0.84 CSF1R (0.54) CSF1RPOLBGAAMAPTLMNA
SCHEMBL4196292 0.81 CSF1R (0.54) CSF1RGAALMNAALDH1A1
SCHEMBL4182584 0.80 CSF1R (0.55) CSF1RGAALMNAALDH1A1
Hydrochloric Acid SCHEMBL5654851 0.74 CSF1R (0.49) CSF1RLMNAALDH1A1SMN1; SMN2MAPK1
SCHEMBL5651332 0.74 CSF1R (0.49) CSF1RLMNAALDH1A1SMN1; SMN2MAPK1
SCHEMBL5736053 0.74 POLB (0.58) KDM4EPOLBGAAMAPTLMNA
SCHEMBL5627956 0.72 SMN1; SMN2 (0.69) KDM4EPOLBGAALMNAALDH1A1
SCHEMBL3073145 0.72 KDM4E (0.64) KDM4EPOLBGAALMNAALDH1A1
Hydrochloric Acid SCHEMBL5653682 0.72 CSF1R (0.52) CSF1R
SCHEMBL4187789 0.72 CSF1R (0.52) CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER CSF1R 111/4885KDM4E 1464/4885POLB 4067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.